Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment
–Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin
–Top-line findings from the second phase of the Phase 1/2 HERA trial show that the primary endpoint for safety was met in the randomized placebo-controlled portion of the study
–$27 million in cash, cash equivalents and short-term investments as of June 30, 2022, expected to be sufficient to fund operations into 2024
–Conference call scheduled for 8:30 a.m. ET today–
Management will host a conference call today at 8:30 a.m. Eastern Time to discuss the Company’s second quarter 2022 financial results and provide a business update.
Dial-in Number
U.S. Dial-in Number: 844-200-6205
Canada Dial-in Number: 833-950-0062
All Other Locations Dial-in Number: 929-526-1599
Access code: 788626
U.S. Replay Dial-in Number: 866-813-9403
Canada Replay Dial-in Number: 226-828-7578
All Other Locations Dial-in Number: 44-204-525-0658
Conference ID: 924827
An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.